PMID- 35805109
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20221002
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 13
DP  - 2022 Jun 25
TI  - GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the 
      Spotlight.
LID - 10.3390/cells11132023 [doi]
LID - 2023
AB  - Defects in brain energy metabolism and proteopathic stress are implicated in 
      age-related degenerative neuronopathies, exemplified by Alzheimer's disease (AD) 
      and Parkinson's disease (PD). As the currently available drug regimens largely 
      aim to mitigate cognitive decline and/or motor symptoms, there is a dire need for 
      mechanism-based therapies that can be used to improve neuronal function and 
      potentially slow down the underlying disease processes. In this context, a new 
      class of pharmacological agents that achieve improved glycaemic control via the 
      glucagon-like peptide 1 (GLP-1) receptor has attracted significant attention as 
      putative neuroprotective agents. The experimental evidence supporting their 
      potential therapeutic value, mainly derived from cellular and animal models of AD 
      and PD, has been discussed in several research reports and review opinions 
      recently. In this review article, we discuss the pathological relevance of 
      derangements in the neurovascular unit and the significance of neuron-glia 
      metabolic coupling in AD and PD. With this context, we also discuss some 
      unresolved questions with regard to the potential benefits of GLP-1 agonists on 
      the neurovascular unit (NVU), and provide examples of novel experimental 
      paradigms that could be useful in improving our understanding regarding the 
      neuroprotective mode of action associated with these agents.
FAU - Monti, Giulia
AU  - Monti G
AUID- ORCID: 0000-0001-9404-1273
AD  - Department of Biomedicine, Aarhus University, Hoegh-Guldbergs Gade 10, DK-8000 
      Aarhus, Denmark.
FAU - Gomes Moreira, Diana
AU  - Gomes Moreira D
AUID- ORCID: 0000-0003-2937-1772
AD  - VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000 Leuven, 
      Belgium.
FAU - Richner, Mette
AU  - Richner M
AD  - Department of Biomedicine, Aarhus University, Hoegh-Guldbergs Gade 10, DK-8000 
      Aarhus, Denmark.
FAU - Mutsaers, Henricus Antonius Maria
AU  - Mutsaers HAM
AD  - Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 
      82, DK-8200 Aarhus, Denmark.
FAU - Ferreira, Nelson
AU  - Ferreira N
AUID- ORCID: 0000-0002-0305-9097
AD  - Department of Biomedicine, Aarhus University, Hoegh-Guldbergs Gade 10, DK-8000 
      Aarhus, Denmark.
FAU - Jan, Asad
AU  - Jan A
AUID- ORCID: 0000-0002-3636-0070
AD  - Department of Biomedicine, Aarhus University, Hoegh-Guldbergs Gade 10, DK-8000 
      Aarhus, Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220625
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Neuroprotective Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - *Alzheimer Disease/drug therapy/metabolism
MH  - Animals
MH  - Glucagon-Like Peptide 1/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/metabolism
MH  - *Neuroprotective Agents/pharmacology/therapeutic use
MH  - *Parkinson Disease/metabolism
PMC - PMC9265397
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Parkinson's disease
OT  - glucagon-like peptide-1 (GLP-1)
OT  - neurodegeneration
OT  - neurovascular unit
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/10 06:00
MHDA- 2022/07/14 06:00
PMCR- 2022/06/25
CRDT- 2022/07/09 01:05
PHST- 2022/06/05 00:00 [received]
PHST- 2022/06/21 00:00 [revised]
PHST- 2022/06/23 00:00 [accepted]
PHST- 2022/07/09 01:05 [entrez]
PHST- 2022/07/10 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/06/25 00:00 [pmc-release]
AID - cells11132023 [pii]
AID - cells-11-02023 [pii]
AID - 10.3390/cells11132023 [doi]
PST - epublish
SO  - Cells. 2022 Jun 25;11(13):2023. doi: 10.3390/cells11132023.